{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T13:04:43Z","timestamp":1768568683845,"version":"3.49.0"},"posted":{"date-parts":[[2025,10,29]]},"group-title":"Oncology","reference-count":55,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.medrxiv.org\/about\/FAQ#license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,10,29]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Durvalumab consolidation after concurrent chemoradiotherapy (cCRT) is the standard-of-care for unresectable stage III non\u2013small cell lung cancer (NSCLC) without actionable driver mutations. However, pneumonitis remains a dose-limiting toxicity that often precludes or interrupts immunotherapy. Conventional predictors based on lung dosimetry alone exhibit limited individual-level discrimination. We investigated whether the thymus, long considered vestigial in adults, influences post-treatment immune recovery and susceptibility to inflammatory toxicity.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We analyzed patients with locally advanced NSCLC treated with cCRT in the RTOG 0617 trial (n = 490) and with standard-of-care cCRT followed by consolidation durvalumab at Memorial Sloan Kettering Cancer Center (MSKCC, n = 230). Percent thymic tissue (pTT), a novel imaging parameter that quantifies the proportion of residual functional thymic tissue on pre-treatment CT scans, was derived using an autosegmentation and Gaussian mixture modeling framework. Logistic regression with restricted cubic splines assessed associations between pTT, mean radiation dose to the thymic region (MDTR), and volume of the lungs receiving \u226520 Gy (lung V20) with high-grade (\u2265 3) pneumonitis.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Across both cohorts, pTT was inversely associated with severe pneumonitis independent of lung V20. Grade 3+ pneumonitis incidence in low-vs high-pTT groups was 7.3% vs 2.9% (p = 0.038) in the RTOG 0617 cohort and 13.9% vs. 5.2% (p = 0.042) in the MSKCC cohort. The combination of low pTT and high lung V20 was associated with the highest rates of severe pneumonitis with 11.5% in RTOG 0617 and 20.8% in MSKCC (compared with 3.3% and 1.9% for high pTT\/low lung V20), identifying a subgroup at particularly high risk. MDTR showed a weaker, non-linear relationship with pneumonitis risk, increasing at moderate doses and declining at the highest radiation exposures.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study established pTT, a quantitative marker of residual functional thymus in adults, as a novel, independent predictor of severe pneumonitis following cCRT with or without consolidation immunotherapy. Incorporating pTT into multimodal risk-stratification frameworks could improve patient selection, personalize radiation planning, and enhance safe delivery of curative-intent cCRT and immunotherapy in locally advanced NSCLC.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2025.10.27.25338565","type":"posted-content","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T21:55:11Z","timestamp":1761774911000},"source":"Crossref","is-referenced-by-count":0,"title":["Thymus Composition Predicts Pneumonitis Risk in Lung Cancer Therapy"],"prefix":"10.64898","author":[{"given":"Tafadzwa L.","family":"Chaunzwa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gokul","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwadwo","family":"Amoako-Boadu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abraham J.","family":"Book","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David G.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biniam","family":"Garomsa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuzhong J.","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaine","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexis","family":"Chidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie E.","family":"Chaft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narek","family":"Shaverdian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel R.","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2025110222101490000_2025.10.27.25338565v1.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809697"},{"key":"2025110222101490000_2025.10.27.25338565v1.2","doi-asserted-by":"crossref","unstructured":"Antonia Scott J. , et al. Durvalumab after Chemoradiotherapy in Stage III Non\u2013Small-Cell Lung Cancer. N. Engl. J. Med. 377, 1919\u20131929.","DOI":"10.1056\/NEJMoa1709937"},{"key":"2025110222101490000_2025.10.27.25338565v1.3","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer","volume":"40","year":"2022","journal-title":"J. Clin. Oncol"},{"key":"2025110222101490000_2025.10.27.25338565v1.4","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr325"},{"key":"2025110222101490000_2025.10.27.25338565v1.5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71207-0"},{"key":"2025110222101490000_2025.10.27.25338565v1.6","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.1016\/j.cllc.2021.07.005","article-title":"CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer","volume":"23","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"2025110222101490000_2025.10.27.25338565v1.7","unstructured":"Girotto, G. et al. Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non\u2013Small Cell Lung Cancer: The Phase III PACIFIC-2 Study. Journal of Clinical Oncology (2025)."},{"key":"2025110222101490000_2025.10.27.25338565v1.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2402614"},{"key":"2025110222101490000_2025.10.27.25338565v1.9","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2012.718093"},{"key":"2025110222101490000_2025.10.27.25338565v1.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2012.04.043"},{"key":"2025110222101490000_2025.10.27.25338565v1.11","doi-asserted-by":"crossref","unstructured":"Marks, L. B. et al. Radiation dose-volume effects in the lung. International journal of radiation oncology, biology, physics 76, (2010).","DOI":"10.1016\/j.ijrobp.2009.06.091"},{"key":"2025110222101490000_2025.10.27.25338565v1.12","doi-asserted-by":"crossref","unstructured":"Rodrigues, G. , Lock, M. , D\u2019Souza, D. , Yu, E. & Van Dyk, J . Prediction of radiation pneumonitis by dose - volume histogram parameters in lung cancer--a systematic review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 71, (2004).","DOI":"10.1016\/j.radonc.2004.02.015"},{"key":"2025110222101490000_2025.10.27.25338565v1.13","doi-asserted-by":"crossref","unstructured":"Rahi, M. S. et al. Radiation-Induced Lung Injury-Current Perspectives and Management. Clinics and practice 11, (2021).","DOI":"10.3390\/clinpract11030056"},{"key":"2025110222101490000_2025.10.27.25338565v1.14","unstructured":"Naidoo, J. et al. Pneumonitis in Patients Treated With Anti-Programmed Death-1\/Programmed Death Ligand 1 Therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 35, (2017)."},{"key":"2025110222101490000_2025.10.27.25338565v1.15","doi-asserted-by":"crossref","unstructured":"Suresh, K. , Naidoo, J. , Lin, C. T. & Danoff, S . Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities. Chest 154, (2018).","DOI":"10.1016\/j.chest.2018.08.1048"},{"key":"2025110222101490000_2025.10.27.25338565v1.16","doi-asserted-by":"crossref","unstructured":"Naidoo, J. et al. Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial. Lung cancer (Amsterdam, Netherlands) 166, (2022).","DOI":"10.1016\/j.lungcan.2022.02.003"},{"key":"2025110222101490000_2025.10.27.25338565v1.17","doi-asserted-by":"crossref","unstructured":"Jan, P. R. , Chang, J. W. & Wu, C. E . Radiation Recall Pneumonitis: A Rare Syndrome That Should Be Recognized. Cancers 14, (2022).","DOI":"10.3390\/cancers14194642"},{"key":"2025110222101490000_2025.10.27.25338565v1.18","doi-asserted-by":"crossref","unstructured":"Smesseim, I. , Mets, O. M. , Daniels, J. M. A. , Bahce, I. & Senan, S . Diagnosis and management of pneumonitis following chemoradiotherapy and immunotherapy in stage III non-small cell lung cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 194, (2024).","DOI":"10.1016\/j.radonc.2024.110147"},{"key":"2025110222101490000_2025.10.27.25338565v1.19","first-page":"1","article-title":"Predictive value of machine learning for radiation pneumonitis and checkpoint inhibitor pneumonitis in lung cancer patients: a systematic review and meta-analysis","volume":"15","year":"2025","journal-title":"Scientific Reports"},{"key":"2025110222101490000_2025.10.27.25338565v1.20","doi-asserted-by":"publisher","DOI":"10.1016\/s0360-3016(99)00183-2"},{"key":"2025110222101490000_2025.10.27.25338565v1.21","first-page":"329","volume":"54","author":"Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional conformal radiation therapy","year":"2002","journal-title":"International Journal of Radiation Oncology*Biology*Physics"},{"key":"2025110222101490000_2025.10.27.25338565v1.22","doi-asserted-by":"crossref","unstructured":"Appelt, A. L. , Vogelius, I. R. , Farr, K. P. , Khalil, A. A. & Bentzen, S. M . Towards individualized dose constraints: Adjusting the QUANTEC radiation pneumonitis model for clinical risk factors. Acta Oncologica 605\u2013612 (2013).","DOI":"10.3109\/0284186X.2013.820341"},{"key":"2025110222101490000_2025.10.27.25338565v1.23","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.ijrobp.2015.10.002","volume":"94","author":"Lung Size and the Risk of Radiation Pneumonitis","year":"2016","journal-title":"International Journal of Radiation Oncology*Biology*Physics"},{"key":"2025110222101490000_2025.10.27.25338565v1.24","doi-asserted-by":"crossref","unstructured":"Meng, Y. et al. Intermediate Dose-Volume Parameters, Not Low-Dose Bath, Is Superior to Predict Radiation Pneumonitis for Lung Cancer Treated With Intensity-Modulated Radiotherapy. Front. Oncol. 10, 584756 (2020).","DOI":"10.3389\/fonc.2020.584756"},{"key":"2025110222101490000_2025.10.27.25338565v1.25","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ijrobp.2008.04.053","volume":"72","author":"Analysis of Radiation Pneumonitis Risk Using a Generalized Lyman Model","year":"2008","journal-title":"International Journal of Radiation Oncology*Biology*Physics"},{"key":"2025110222101490000_2025.10.27.25338565v1.26","doi-asserted-by":"crossref","unstructured":"Liang, B. et al. Dosiomics: Extracting 3D Spatial Features From Dose Distribution to Predict Incidence of Radiation Pneumonitis. Front. Oncol. 9, 445065 (2019).","DOI":"10.3389\/fonc.2019.00269"},{"key":"2025110222101490000_2025.10.27.25338565v1.27","first-page":"1","article-title":"Multicenter development of a deep learning radiomics and dosiomics nomogram to predict radiation pneumonia risk in non-small cell lung cancer","volume":"15","year":"2025","journal-title":"Scientific Reports"},{"key":"2025110222101490000_2025.10.27.25338565v1.28","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3857\/roj.2013.31.1.34","article-title":"Predictors of radiation pneumonitis and pulmonary function changes after concurrent chemoradiotherapy of non-small cell lung cancer","volume":"31","year":"2013","journal-title":"Radiat Oncol J"},{"key":"2025110222101490000_2025.10.27.25338565v1.29","doi-asserted-by":"crossref","unstructured":"Cousin, F. et al. Machine Learning Model Integrating CT Radiomics of the Lung to Predict Checkpoint Inhibitor Pneumonitis in Patients with Advanced Cancer. Technol Cancer Res Treat 24, 15330338251344004 (2025).","DOI":"10.1177\/15330338251344004"},{"key":"2025110222101490000_2025.10.27.25338565v1.30","doi-asserted-by":"crossref","unstructured":"Foy, J. J. , Armato, S. G. & Al-Hallaq, H. A . Effects of variability in radiomics software packages on classifying patients with radiation pneumonitis. Journal of medical imaging (Bellingham, Wash.) 7, (2020).","DOI":"10.1117\/1.JMI.7.1.014504"},{"key":"2025110222101490000_2025.10.27.25338565v1.31","doi-asserted-by":"publisher","DOI":"10.1101\/2025.10.20.25338395"},{"key":"2025110222101490000_2025.10.27.25338565v1.32","doi-asserted-by":"crossref","unstructured":"Zhang, J. et al. Dosimetric Effect of Thymus and Thoracic Duct on Radiation-Induced Lymphopenia in Patients With Primary Lung Cancer Who Received Thoracic Radiation. Advances in radiation oncology 8, (2023).","DOI":"10.1016\/j.adro.2023.101260"},{"key":"2025110222101490000_2025.10.27.25338565v1.33","unstructured":"Deniz, S. , et al. Effect of Rebound Thymic Hyperplasia on Survival in Chemotherapy-Treated Lung Cancer. Turkish thoracic journal 21, (2020)."},{"key":"2025110222101490000_2025.10.27.25338565v1.34","doi-asserted-by":"crossref","unstructured":"Cardinale, A. , De Luca, C. D. , Locatelli, F. & Velardi, E . Thymic Function and T-Cell Receptor Repertoire Diversity: Implications for Patient Response to Checkpoint Blockade Immunotherapy. Frontiers in immunology 12, (2021).","DOI":"10.3389\/fimmu.2021.752042"},{"key":"2025110222101490000_2025.10.27.25338565v1.35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2302892"},{"key":"2025110222101490000_2025.10.27.25338565v1.36","doi-asserted-by":"crossref","unstructured":"Sun, D.-P. et al. Investigating Factors Associated with Thymic Regeneration after Chemotherapy in Patients with Lymphoma. Front. Immunol. 7, 234558 (2016).","DOI":"10.3389\/fimmu.2016.00654"},{"key":"2025110222101490000_2025.10.27.25338565v1.37","doi-asserted-by":"crossref","unstructured":"Okamura, Y. T. et al. Automated Quantitative Evaluation of Age-Related Thymic Involution on Plain Chest CT. Annals of biomedical engineering 53, (2025).","DOI":"10.1007\/s10439-025-03805-z"},{"key":"2025110222101490000_2025.10.27.25338565v1.38","doi-asserted-by":"publisher","DOI":"10.1101\/2023.11.13.23298440"},{"key":"2025110222101490000_2025.10.27.25338565v1.39","doi-asserted-by":"crossref","unstructured":"Guo, Y. et al. Development and validation of AI-based automatic segmentation and measurement of thymus on chest CT scans. BMC medical imaging 25, (2025).","DOI":"10.1186\/s12880-025-01783-1"},{"key":"2025110222101490000_2025.10.27.25338565v1.40","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.21037\/tlcr-24-203","article-title":"Association between thymus density loss and efficacy in non-small cell lung cancer patients treated with immune checkpoint inhibitors","volume":"13","year":"2024","journal-title":"Translational Lung Cancer Research"},{"key":"2025110222101490000_2025.10.27.25338565v1.41","doi-asserted-by":"publisher","DOI":"10.1007\/s10278-013-9622-7"},{"key":"2025110222101490000_2025.10.27.25338565v1.42","doi-asserted-by":"crossref","unstructured":"Discacciati, A. et al. Estimating and presenting non-linear associations with restricted cubic splines. International journal of epidemiology 54, (2025).","DOI":"10.1093\/ije\/dyaf088"},{"key":"2025110222101490000_2025.10.27.25338565v1.43","doi-asserted-by":"crossref","unstructured":"Wang, X. et al. A review of radiation-induced lymphopenia in patients with esophageal cancer: an immunological perspective for radiotherapy. Therapeutic Advances in Medical Oncology 12, 1758835920926822 (2020).","DOI":"10.1177\/1758835920926822"},{"key":"2025110222101490000_2025.10.27.25338565v1.44","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13671"},{"key":"2025110222101490000_2025.10.27.25338565v1.45","doi-asserted-by":"crossref","unstructured":"Thomas, R. , Wang, W. & Su, D. M . Contributions of Age-Related Thymic Involution to Immunosenescence and Inflammaging. Immunity & ageing : I & A 17, (2020).","DOI":"10.1186\/s12979-020-0173-8"},{"key":"2025110222101490000_2025.10.27.25338565v1.46","doi-asserted-by":"crossref","unstructured":"Palmer, D. B . The effect of age on thymic function. Frontiers in immunology 4, (2013).","DOI":"10.3389\/fimmu.2013.00316"},{"key":"2025110222101490000_2025.10.27.25338565v1.47","doi-asserted-by":"crossref","unstructured":"Dhabhar, F. S . Enhancing versus suppressive effects of stress on immune function: implications for immunoprotection and immunopathology. Neuroimmunomodulation 16, (2009).","DOI":"10.1159\/000216188"},{"key":"2025110222101490000_2025.10.27.25338565v1.48","doi-asserted-by":"crossref","unstructured":"Yeager, M. P. , Pioli, P. A. & Guyre, P. M . Cortisol exerts bi-phasic regulation of inflammation in humans. Dose-response : a publication of International Hormesis Society 9, (2011).","DOI":"10.2203\/dose-response.10-013.Yeager"},{"key":"2025110222101490000_2025.10.27.25338565v1.49","doi-asserted-by":"crossref","unstructured":"Lumniczky, K. et al. Low dose ionizing radiation effects on the immune system. Environment international 149, (2021).","DOI":"10.1016\/j.envint.2020.106212"},{"key":"2025110222101490000_2025.10.27.25338565v1.50","doi-asserted-by":"crossref","unstructured":"Emami, B. et al. Tolerance of normal tissue to therapeutic irradiation. International journal of radiation oncology, biology, physics 21, (1991).","DOI":"10.1016\/0360-3016(91)90171-Y"},{"key":"2025110222101490000_2025.10.27.25338565v1.51","doi-asserted-by":"crossref","unstructured":"Bentzen, S. M. et al. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. International journal of radiation oncology, biology, physics 76, (2010).","DOI":"10.1016\/j.ijrobp.2009.09.040"},{"key":"2025110222101490000_2025.10.27.25338565v1.52","doi-asserted-by":"crossref","unstructured":"Marks, L. B. et al. Use of normal tissue complication probability models in the clinic. International journal of radiation oncology, biology, physics 76, (2010).","DOI":"10.1016\/j.ijrobp.2009.07.1754"},{"key":"2025110222101490000_2025.10.27.25338565v1.53","doi-asserted-by":"crossref","unstructured":"Paun, A. , Kunwar, A. & Haston, C. K . Acute adaptive immune response correlates with late radiation-induced pulmonary fibrosis in mice. Radiation oncology (London , England ) 10, (2015).","DOI":"10.1186\/s13014-015-0359-y"},{"key":"2025110222101490000_2025.10.27.25338565v1.54","doi-asserted-by":"crossref","first-page":"307","DOI":"10.21037\/tlcr-22-108","article-title":"Exploration of radiation-induced lung injury, from mechanism to treatment: a narrative review","volume":"11","year":"2022","journal-title":"Transl Lung Cancer Res"},{"key":"2025110222101490000_2025.10.27.25338565v1.55","doi-asserted-by":"crossref","unstructured":"Peters, S. et al. 65O CheckMate 73L: Phase III study comparing nivolumab (N) + concurrent chemoradiotherapy (CCRT) followed by N \u00b1 ipilimumab (I) v CCRT followed by durvalumab (D) for previously untreated, locally advanced stage (stg) III NSCLC. Immunooncol. Technol. 24, 100808 (2024).","DOI":"10.1016\/j.iotech.2024.100808"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.10.27.25338565","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:49:46Z","timestamp":1768510186000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2025.10.27.25338565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":55,"URL":"https:\/\/doi.org\/10.1101\/2025.10.27.25338565","relation":{},"subject":[],"published":{"date-parts":[[2025,10,29]]},"subtype":"preprint"}}